As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
REGULATORY
Experts Urge MHLW to Present Detailed Data on Generic Manufacturing Costs
Academic experts on the health ministry’s panel on comprehensive pharmaceutical measures on October 12 leaned on the regulator to provide additional documents on generic manufacturing costs so as to take a closer look into the data that have been presented…
To read the full story
Related Article
- Nearly 700 Key Drugs Found to Be Unprofitable Due to Inflation, FX: Survey
October 24, 2022
- Ways to Resolve Drug Lag/Loss, Fuel Development in Japan Up for Debate: MHLW Panel
October 13, 2022
- Panel Members Want More Data on Allocation of NHI-Market Price Margins
October 13, 2022
- MHLW Expert Panel Sorts Out Discussion Points for Full Debate; Focus on Innovation, Stable Supply, and Margins
October 13, 2022
REGULATORY
- Opposition Party Member Calls for Chuikyo Reform
January 27, 2025
- Drug Discovery Fund Not Mentioned in Ruling Party Document; All Eyes on Bill’s Review on Jan. 27
January 24, 2025
- MHLW Eyes 2 Biz Models as It Pushes Generic Industry Shakeup: Minister
January 23, 2025
- Draft Bill to Amend PMD Act Up for LDP Review on Jan. 27
January 23, 2025
- How’s Drug Discovery Fund Different from AMED? LDP Member Says It’s Too Early to Submit Legislation
January 22, 2025
A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…